ENDOMETRIAL NEOPLASMS
Clinical trials for ENDOMETRIAL NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL NEOPLASMS trials appear
Sign up with your email to follow new studies for ENDOMETRIAL NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink hard-to-treat tumors
Disease control OngoingThis study tests a new drug called E7386 combined with other anticancer drugs in people with advanced solid tumors, including liver, colorectal, and endometrial cancers. The main goals are to check safety and find the best dose. About 300 adults are taking part in this early-phas…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 17, 2026 02:40 UTC
-
New drug combo shows promise in slowing endometrial cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy, followed by maintenance therapy with or without olaparib, can help people with newly diagnosed advanced or recurrent endometrial cancer live longer without their cancer growing. About 805 …
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 17, 2026 02:30 UTC
-
New pill targets hard-to-treat cancers with KRAS mutation
Disease control OngoingThis study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
Immunotherapy may outperform chemo for certain uterine cancers
Disease control OngoingThis study compares the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) in 280 women with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR. Participants have not had prior chemotherapy for the…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug BL-M17D1 targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New drug targets HER2 cancers in phase 2 trial
Disease control OngoingThis study tests an experimental drug called disitamab vedotin in people with advanced head and neck, lung, endometrial, or ovarian cancers that have a HER2 marker. The drug is designed to stick to cancer cells and kill them. About 120 adults will receive the drug every two weeks…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC